Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynavax Hepatitis B Vaccine Could Get Comparative Post-Market Autoimmunity Assessment

This article was originally published in The Pink Sheet Daily

Executive Summary

The observational study would look at Dynavax’s Heplisav and GlaxoSmithKline’s Energerix-B, according to FDA briefing materials for the Vaccines and Related Biological Products Advisory Committee’s Nov. 15 review of Heplisav for adults 18 to 70 years of age.

Advertisement

Related Content

Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population
Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population
Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav
FDA Panel Considers Dynavax’s Heplisav Safety Database Insufficient
Dynavax’s Heplisav Heads To Advisory Panel, But Will It Drudge Up Old Safety Issues?
FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population
Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel